Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (8): 735-740.DOI: 10.3969/j.issn.1673-8640.2022.08.006
Previous Articles Next Articles
LIU Xingqiang, NING Lifen(), LI Lin, CHEN Zhongcheng
Received:
2021-05-17
Revised:
2021-11-10
Online:
2022-08-30
Published:
2022-09-16
Contact:
NING Lifen
CLC Number:
LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR+-CTC,ANXA2 and ProGRP[J]. Laboratory Medicine, 2022, 37(8): 735-740.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.08.006
组别 | 例数 | FR+-CTC/(FU/3 mL) | ANXA2/(ng/mL) | ProGRP/(pg/mL) |
---|---|---|---|---|
肺癌组 | 116 | 12.15±2.57 | 33.78±3.67 | 126.73±17.35 |
对照组 | 100 | 5.41±1.22 | 18.59±2.83 | 38.89±6.73 |
t值 | 26.765 | 23.641 | 19.544 | |
P值 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | FR+-CTC/(FU/3 mL) | ANXA2/(ng/mL) | ProGRP/(pg/mL) |
---|---|---|---|---|
肺癌组 | 116 | 12.15±2.57 | 33.78±3.67 | 126.73±17.35 |
对照组 | 100 | 5.41±1.22 | 18.59±2.83 | 38.89±6.73 |
t值 | 26.765 | 23.641 | 19.544 | |
P值 | <0.001 | <0.001 | <0.001 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
FR+-CTC | 0.885(0.833~0.930) | 8.70 FU/3 mL | 82.1 | 81.7 | 63.8 |
ANXA2 | 0.810(0.780~0.886) | 26.80 ng/mL | 72.0 | 83.0 | 55.0 |
ProGRP | 0.696(0.608~0.735) | 70.50 pg/mL | 85.0 | 60.1 | 45.1 |
联合检测 | 0.935(0.906~0.973) | 0.284 | 90.1 | 84.5 | 74.6 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
FR+-CTC | 0.885(0.833~0.930) | 8.70 FU/3 mL | 82.1 | 81.7 | 63.8 |
ANXA2 | 0.810(0.780~0.886) | 26.80 ng/mL | 72.0 | 83.0 | 55.0 |
ProGRP | 0.696(0.608~0.735) | 70.50 pg/mL | 85.0 | 60.1 | 45.1 |
联合检测 | 0.935(0.906~0.973) | 0.284 | 90.1 | 84.5 | 74.6 |
指标 | CYFRA21-1 | NSE | SCC-Ag | |||||
---|---|---|---|---|---|---|---|---|
r值 | P值 | r值 | P值 | r值 | P值 | |||
FR+-CTC | 0.691 | 0.001 | 0.502 | 0.008 | 0.457 | 0.005 | ||
ANXA2 | 0.710 | 0.003 | 0.371 | 0.009 | 0.411 | 0.004 | ||
ProGRP | 0.568 | 0.005 | 0.542 | 0.007 | 0.601 | 0.006 |
指标 | CYFRA21-1 | NSE | SCC-Ag | |||||
---|---|---|---|---|---|---|---|---|
r值 | P值 | r值 | P值 | r值 | P值 | |||
FR+-CTC | 0.691 | 0.001 | 0.502 | 0.008 | 0.457 | 0.005 | ||
ANXA2 | 0.710 | 0.003 | 0.371 | 0.009 | 0.411 | 0.004 | ||
ProGRP | 0.568 | 0.005 | 0.542 | 0.007 | 0.601 | 0.006 |
临床病理特征 | 例数 | FR+-CTC/(FU/3 mL) | ANXA2/(ng/mL) | ProGRP/(pg/mL) |
---|---|---|---|---|
年龄 | ||||
≥60岁 | 68 | 12.24±2.19 | 33.89±3.54 | 127.01±18.33 |
<60岁 | 48 | 12.03±2.67 | 33.71±3.72 | 126.58±17.59 |
t值 | 2.688 | 1.147 | 1.753 | |
P值 | 0.564 | 0.443 | 0.498 | |
性别 | ||||
男 | 76 | 12.36±2.01 | 33.96±3.49 | 126.98±18.03 |
女 | 40 | 12.11±2.47 | 33.21±3.03 | 126.44±17.75 |
t值 | 2.775 | 1.542 | 1.673 | |
P值 | 0.580 | 0.499 | 0.562 | |
吸烟史 | ||||
有 | 70 | 13.01±2.33 | 34.01±4.02 | 128.43±18.45 |
无 | 46 | 11.54±2.05 | 31.37±3.59 | 124.52±17.67 |
t值 | 8.587 | 7.021 | 8.907 | |
P值 | 0.026 | 0.020 | 0.013 | |
好发部位 | ||||
左肺 | 47 | 12.54±2.11 | 34.21±3.89 | 127.50±18.06 |
右肺 | 69 | 12.01±2.47 | 33.15±3.57 | 126.69±17.52 |
t值 | 2.119 | 1.769 | 2.003 | |
P值 | 0.563 | 0.642 | 0.586 | |
TNM分期 | ||||
Ⅰ~Ⅱ期 | 78 | 10.66±1.56 | 30.44±3.89 | 120.45±15.52 |
Ⅲ~Ⅳ期 | 38 | 12.97±2.21 | 35.65±3.50 | 130.27±17.39 |
t值 | 8.440 | 8.002 | 8.455 | |
P值 | 0.000 | 0.000 | 0.000 | |
肿瘤直径 | ||||
≥5 cm | 78 | 13.09±1.52 | 38.76±4.52 | 137.55±18.07 |
<5 cm | 38 | 9.99±1.79 | 30.56±3.61 | 100.68±15.09 |
t值 | 15.465 | 16.774 | 11.349 | |
P值 | 0.000 | 0.000 | 0.000 | |
分化程度 | ||||
高分化 | 74 | 10.03±1.43 | 38.45±4.43 | 141.36±16.47 |
低分化 | 42 | 12.99±1.55 | 30.34±1.55 | 119.46±14.70 |
t值 | 11.098 | 16.783 | 17.334 | |
P值 | 0.000 | 0.000 | 0.000 | |
淋巴结转移 | ||||
有 | 46 | 13.75±1.40 | 39.33±5.52 | 140.75±14.55 |
无 | 70 | 11.77±1.63 | 31.79±5.76 | 120.87±16.59 |
t值 | 11.237 | 14.566 | 16.774 | |
P值 | 0.000 | 0.000 | 0.000 | |
远隔转移 | ||||
有 | 18 | 13.45±1.44 | 38.46±4.59 | 138.49±14.59 |
无 | 98 | 11.87±2.00 | 32.15±5.54 | 124.18±16.09 |
t值 | 12.354 | 21.775 | 19.457 | |
P值 | 0.000 | 0.000 | 0.000 |
临床病理特征 | 例数 | FR+-CTC/(FU/3 mL) | ANXA2/(ng/mL) | ProGRP/(pg/mL) |
---|---|---|---|---|
年龄 | ||||
≥60岁 | 68 | 12.24±2.19 | 33.89±3.54 | 127.01±18.33 |
<60岁 | 48 | 12.03±2.67 | 33.71±3.72 | 126.58±17.59 |
t值 | 2.688 | 1.147 | 1.753 | |
P值 | 0.564 | 0.443 | 0.498 | |
性别 | ||||
男 | 76 | 12.36±2.01 | 33.96±3.49 | 126.98±18.03 |
女 | 40 | 12.11±2.47 | 33.21±3.03 | 126.44±17.75 |
t值 | 2.775 | 1.542 | 1.673 | |
P值 | 0.580 | 0.499 | 0.562 | |
吸烟史 | ||||
有 | 70 | 13.01±2.33 | 34.01±4.02 | 128.43±18.45 |
无 | 46 | 11.54±2.05 | 31.37±3.59 | 124.52±17.67 |
t值 | 8.587 | 7.021 | 8.907 | |
P值 | 0.026 | 0.020 | 0.013 | |
好发部位 | ||||
左肺 | 47 | 12.54±2.11 | 34.21±3.89 | 127.50±18.06 |
右肺 | 69 | 12.01±2.47 | 33.15±3.57 | 126.69±17.52 |
t值 | 2.119 | 1.769 | 2.003 | |
P值 | 0.563 | 0.642 | 0.586 | |
TNM分期 | ||||
Ⅰ~Ⅱ期 | 78 | 10.66±1.56 | 30.44±3.89 | 120.45±15.52 |
Ⅲ~Ⅳ期 | 38 | 12.97±2.21 | 35.65±3.50 | 130.27±17.39 |
t值 | 8.440 | 8.002 | 8.455 | |
P值 | 0.000 | 0.000 | 0.000 | |
肿瘤直径 | ||||
≥5 cm | 78 | 13.09±1.52 | 38.76±4.52 | 137.55±18.07 |
<5 cm | 38 | 9.99±1.79 | 30.56±3.61 | 100.68±15.09 |
t值 | 15.465 | 16.774 | 11.349 | |
P值 | 0.000 | 0.000 | 0.000 | |
分化程度 | ||||
高分化 | 74 | 10.03±1.43 | 38.45±4.43 | 141.36±16.47 |
低分化 | 42 | 12.99±1.55 | 30.34±1.55 | 119.46±14.70 |
t值 | 11.098 | 16.783 | 17.334 | |
P值 | 0.000 | 0.000 | 0.000 | |
淋巴结转移 | ||||
有 | 46 | 13.75±1.40 | 39.33±5.52 | 140.75±14.55 |
无 | 70 | 11.77±1.63 | 31.79±5.76 | 120.87±16.59 |
t值 | 11.237 | 14.566 | 16.774 | |
P值 | 0.000 | 0.000 | 0.000 | |
远隔转移 | ||||
有 | 18 | 13.45±1.44 | 38.46±4.59 | 138.49±14.59 |
无 | 98 | 11.87±2.00 | 32.15±5.54 | 124.18±16.09 |
t值 | 12.354 | 21.775 | 19.457 | |
P值 | 0.000 | 0.000 | 0.000 |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
FR+-CTC | 0.328 | 0.342 | 4.405 | 0.000 | 1.385(1.187~4.974) |
ANXA2 | 0.511 | 0.442 | 4.053 | 0.000 | 1.774(1.601~5.075) |
ProGRP | 0.632 | 0.380 | 4.509 | 0.000 | 1.823(1.677~6.005) |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
FR+-CTC | 0.328 | 0.342 | 4.405 | 0.000 | 1.385(1.187~4.974) |
ANXA2 | 0.511 | 0.442 | 4.053 | 0.000 | 1.774(1.601~5.075) |
ProGRP | 0.632 | 0.380 | 4.509 | 0.000 | 1.823(1.677~6.005) |
[1] | 陈盔, 王建刚, 韩娉怡. 体检肺癌筛查与健康管理的新模式探讨[J]. 中华健康管理学杂志, 2022, 16(3):199-203. |
[2] |
SHROFF G S, DE GROOT P M, PAPADIMITRAKOPOULOU V A, et al. Targeted therapy and immunotherapy in the treatment of non-small cell lung cancer[J]. Radiol Clin North Am, 2018, 56(3):485-495.
DOI URL |
[3] | 余芳, 王存吉, 胡亚. 血清微小RNA-296、CC趋化因子受体3表达与非小细胞肺癌复发转移的相关性分析[J]. 中国临床医生杂志, 2021, 49(1):44-48. |
[4] | 李倩, 郑琪, 马婕群, 等. 叶酸受体阳性循环肿瘤细胞检测的临床研究进展[J]. 标记免疫分析与临床, 2020, 27(2):356-360. |
[5] |
MA S, LU C C, YANG L Y, et al. ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis[J]. J Exp Clin Cancer Res, 2018, 37(1):183.
DOI URL |
[6] | 李会萍, 郑大勇, 杨帅, 等. 血清胃泌素释放肽前体在小细胞肺癌中的临床价值[J]. 检验医学, 2020, 35(4):310-313. |
[7] | 赫捷, 李霓, 陈万青, 等. 中国肺癌筛查与早诊早治指南(2021,北京)[J]. 中华肿瘤杂志, 2021, 43(3):243-268. |
[8] | 杨龙海, 叶波, 魏星, 等. 最新国际肺癌TNM分期标准(第8版)修订稿解读[J]. 中国医刊, 2016, 51(9):22-25. |
[9] | 苏振华, 章怀成, 江强. 肺癌患者血小板参数与其临床病理特征相关性分析[J]. 检验医学, 2020, 35(5):461-463. |
[10] | 李雪琴, 陈中文, 金鎏, 等. 2010年至2014年浙江省肿瘤登记地区肺癌发病和死亡情况分析[J]. 中国肿瘤临床, 2018, 45(22):1151-1154. |
[11] |
CHENG B, XIONG S, LI C, et al. An annual review of the remarkable advances in lung cancer clinical research in 2019[J]. J Thorac Dis, 2020, 12(3):1056-1069.
DOI URL |
[12] | 何雨笑, 鲁继斌. 循环肿瘤细胞对NSCLC浸润深度的评估[J]. 临床肺科杂志, 2020, 25(10):1468-1472. |
[13] |
CHEN L, PENG M, LI N, et al. Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer[J]. Sci Rep, 2018, 8(1):1188.
DOI URL |
[14] | 唐兴, 蒋东, 赵军. 外周血叶酸受体阳性循环肿瘤细胞检测在非小细胞肺癌筛查中的应用价值[J]. 中华实用诊断与治疗杂志, 2021, 35(3):280-283. |
[15] |
ZHOU Q, GENG Q, WANG L, et al. Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules:a non-invasive biomarker for predicting malignancy and tumour invasiveness[J]. EBioMedicine, 2019, 41:236-243.
DOI URL |
[16] |
CHEN X, ZHOU F, LI X, et al. Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer[J]. Ann Transl Med, 2020, 8(10):631.
DOI URL |
[17] |
MURPHY A G, FOLEY K, RUCKI A A, et al. Stromal annexin A2 expression is predictive of decreased survival in pancreatic cancer[J]. Oncotarget, 2017, 8(63):106405-106414.
DOI URL |
[18] | 马永峰, 要莉莉, 刘利, 等. NSCLC患者组织中SIRT2、ProGRP、CHCHD2表达情况与临床病理特征及预后的关系[J]. 国际检验医学杂志, 2021, 42(1):75-77. |
[1] | ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811. |
[2] | CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639. |
[3] | YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy [J]. Laboratory Medicine, 2023, 38(4): 342-346. |
[4] | SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351. |
[5] | DAI Jianmin, CHEN Nuo, WEI Jian. Changes of serum ProGRP,NSE and CYFRA21-1 levels among the patients with different stages of chronic kidney disease [J]. Laboratory Medicine, 2022, 37(9): 811-814. |
[6] | ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355. |
[7] | WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359. |
[8] | XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163. |
[9] | MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer [J]. Laboratory Medicine, 2022, 37(1): 56-59. |
[10] | XU Runhao, ZOU Chen, ZHANG Jie, LI Min, ZHANG Shulin. Application of serum bile acid spectrum in the differential diagnosis of pneumonia and lung cancer [J]. Laboratory Medicine, 2021, 36(1): 1-7. |
[11] | PENG Jiaowu, SUN Chengmou. Diagnostic value of miR-124a and miR-449a in plasma of non-small cell lung cancer [J]. Laboratory Medicine, 2021, 36(1): 34-38. |
[12] | WANG Zijin, ZHANG Xiaoying. Role of apolipoprotein M in the proliferation,migration and invasion of non-small cell lung cancer A549 cells [J]. Laboratory Medicine, 2020, 35(9): 937-942. |
[13] | LIU Qin, CHEN Chong, YUE Chao. Role of an elevated D-dimer cut-off value for the prognosis of lung cancer [J]. Laboratory Medicine, 2020, 35(8): 763-766. |
[14] | YUAN Shiyang, LIU Chuan, OUYANG Xiaochun, XIE Junping, HE Rongzhi, LI Lixiang, ZOU Yeqing. Clinical significance of detecting plasma EGFR T790M gene mutation in patients with NSCLC by 3D digital PCR [J]. Laboratory Medicine, 2020, 35(8): 806-810. |
[15] | LI Huiping, ZHENG Dayong, YANG Shuai, ZHOU Yunli. Role of serum pro-gastrin releasing peptide in patients with small cell lung cancer [J]. Laboratory Medicine, 2020, 35(4): 310-313. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||